AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$KROS

Lerner Lorena Raquel sold $37K of KROS

Lerner Lorena Raquel (Chief Scientific Officer) sold 3,568 shares of Keros Therapeutics, Inc. (KROS) at $10.29 on 2026-08-18.

Original reporting
SEC EDGAR · Lerner Lorena Raquel
Published Aug 20, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KROS
Neutral
high confidence
Mentioned
$KROS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KROSNeutralLow
01

Why it matters

The sale is modest and does not suggest a material change in company outlook.

02

Market read

Insider sale is routine; limited trading relevance.

03

What to watch

Potential upcoming clinical trial results or regulatory decisions not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date Aug 20, 2026

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$KROSNeutralHigh confidence
Context

Chief Scientific Officer sold 3,568 shares for $36.7K on Aug 18, 2026, reducing her stake to 27,559 shares.

Expected impact

No significant impact; price may stay flat.

Evidence & confidence

The sale size is small relative to market cap and disclosed via Form 4, indicating routine portfolio adjustment.

Market effects

Sector

No broader sector impact; biotech insider sales are common.

Regional

None

Global

None

Counterpoint

What could challenge this read

If the insider anticipates near-term downside, the sell could hint at upcoming negative news.

Key entities

  • person
    Lerner Lorena Raquel

    Chief Scientific Officer of Keros Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KROS insider trading history →

Related articles

SEP 28
$KROSMedAI 8/10

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD • Initial data expected in the first half of 2027 LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: K

SEC EDGAR 8-K2 min